APOE and Alzheimer disease: To address this, all analyses were controlled for APOE ε4 carrier status; also, we could previously show that the LFC supports reserve across both normal aging and subjects at increased AD risk, supporting a more general role of the LFC for reserve in both normal and pathological aging [13].